Latest / The Well-Built Life / Cell Death Dynamics
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell alongside Thomas Bennett and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get
- 0:21Speaker 1: comfortable and let's dive in. So let's dive into the
- 0:24Speaker 1: fascinating journey of how scientists unraveled the complex landscape of
- 0:29Speaker 1: cell death. starting with apoptosis, the first form of programmed
- 0:33Speaker 1: cell death identified back in 1972 by Kerr, Willey, and Curry.
- 0:38Speaker 1: They described it as programmed cell death, a term that
- 0:42Speaker 1: fundamentally changed how we look at the process.
- 0:44Speaker 2: Right, and that's the crucial nuance here, because before their work,
- 0:48Speaker 2: cell death was often seen as accidental or as a
- 0:51Speaker 2: mere failure. But Kerr and his colleagues showed us that
- 0:54Speaker 2: cells actually have a way to selectively end their own lives,
- 0:58Speaker 2: a process that's tightly regulated. This laid the foundational understanding
- 1:02Speaker 2: that's critical for later research.
- 1:04Speaker 1: Exactly, which brings up an interesting contradiction. While apoptosis is
- 1:09Speaker 1: tightly regulated, the other forms of cell death, like necrosis,
- 1:14Speaker 1: can be quite chaotic. Necrosis is more of a blunt,
- 1:18Speaker 1: uncontrolled process, often resulting from acute injuries. This dichotomy makes
- 1:23Speaker 1: it tricky to understand the differences and how they play
- 1:27Speaker 1: out in real biological systems.
- 1:29Speaker 2: That's a great point. And as we move into the 1980s,
- 1:34Speaker 2: with the identification of caspases by Martin Chalfie, we started
- 1:38Speaker 2: to see the mechanics of apoptosis in more detail. Caspases,
- 1:42Speaker 2: particularly caspase-3 and caspase-7, orchestrate the dismantling of the cell.
- 1:49Speaker 2: How do you think their discovery influenced our understanding of
- 1:53Speaker 2: cell death?
- 1:53Speaker 1: It definitely transformed the narrative from vague notions of cell
- 1:57Speaker 1: death to a more precise and mechanistic understanding. Now we
- 2:01Speaker 1: can see how cells use these caspases to cleave proteins
- 2:05Speaker 1: specifically for the dismantling process. It's like the cell is
- 2:09Speaker 1: carefully breaking everything down, instead of just disintegrating chaotically.
- 2:14Speaker 2: And as we transition into the 90s, key players like
- 2:17Speaker 2: the intrinsic and extrinsic apoptosis pathways were outlined, and the
- 2:21Speaker 2: concept of necrosis as an inflammatory form of cell death crystallized.
- 2:26Speaker 2: How do you think these findings might have affected how
- 2:28Speaker 2: researchers viewed the broader picture of cell death?
- 2:30Speaker 1: Well, these findings were pivotal because they showed us that
- 2:33Speaker 1: the ways cells die aren't so different. Epoptosis and necrosis
- 2:37Speaker 1: both have their roles, but they are just different mechanisms
- 2:41Speaker 1: leading to similar outcomes. But then, as we move into
- 2:45Speaker 1: the 2000s, something really interesting happens with the discovery of
- 2:49Speaker 1: pyroptosis and necroptosis.
- 2:51Speaker 2: Absolutely. The identification of pyroptosis, primarily in immune cells, and
- 2:57Speaker 2: necroptosis as a specialized form of necrosis, adds a whole
- 3:01Speaker 2: new layer of complexity. Gastramin proteins and RIP-1-3 are the
- 3:06Speaker 2: key players in these processes, and they have really changed
- 3:09Speaker 2: our understanding of how inflammatory responses are linked to cell death.
- 3:14Speaker 1: It's like the cell is playing different roles. It can
- 3:16Speaker 1: be calmly dismantling itself, apoptosis. or it can be part
- 3:20Speaker 1: of a fiery, inflammatory response, pyroptosis, or it can be
- 3:25Speaker 1: the uncontrolled, damaging process we see in necrotic scenarios. Each
- 3:30Speaker 1: of these forms has its own unique pathway and signaling.
- 3:34Speaker 2: And as we step into the 2010s, pyroptosis emerges, bringing
- 3:38Speaker 2: with it the role of iron-dependent lipid peroxidation in causing
- 3:42Speaker 2: cell death. This ties directly into the inflammatory responses seen
- 3:46Speaker 2: in apoptosis and necrosis. So, You think this form of
- 3:50Speaker 2: cell death is particularly relevant for understanding chronic inflammatory conditions?
- 3:56Speaker 1: Definitely. Ferruptosis is a form of cell death that's closely
- 4:00Speaker 1: linked to oxidative stress, so it's particularly relevant for conditions
- 4:04Speaker 1: like Alzheimer's disease and Parkinson's. It helps us see how
- 4:08Speaker 1: cell death isn't just about the cell itself, but also
- 4:11Speaker 1: about the environment around it.
- 4:13Speaker 2: And as we look at the stakeholders, like the different
- 4:15Speaker 2: cellular components and signaling pathways involved … It's clear that
- 4:20Speaker 2: understanding these mechanisms is a bit like solving a complex puzzle.
- 4:25Speaker 2: Each piece, mitochondria, caspases, gastroman proteins, and RIP, one-third, plays
- 4:30Speaker 2: a crucial role. How do you think this interplay of
- 4:33Speaker 2: factors affects disease states, especially in chronic inflammatory conditions?
- 4:38Speaker 1: That's a great question. The interplay between these factors complicates
- 4:42Speaker 1: the therapeutic landscape significantly. For instance … Manipulating these pathways
- 4:48Speaker 1: for therapeutic purposes needs precision. We need to know exactly
- 4:52Speaker 1: how to target and modulate these processes without causing unintended harm.
- 4:57Speaker 2: Exactly. And as our understanding deepens, so too do the
- 5:01Speaker 2: questions like how do we precisely manipulate programmed cell death
- 5:05Speaker 2: pathways for therapeutic purposes? And can we develop therapies that
- 5:09Speaker 2: leverage these cell death mechanisms to combat chronic inflammatory diseases
- 5:13Speaker 2: and other conditions?
- 5:14Speaker 1: These are the kinds of questions that keep researchers up
- 5:17Speaker 1: at night. The future of cell death research is really exciting,
- 5:22Speaker 1: with potential for groundbreaking therapies that could revolutionize how we
- 5:25Speaker 1: treat a wide range of diseases. And with ongoing research,
- 5:30Speaker 1: we might see more precise and less invasive medical interventions
- 5:34Speaker 1: in the years to come. All right, Thomas, let's dig
- 5:37Speaker 1: into the mechanics of these cell death pathways, starting with apoptosis,
- 5:42Speaker 1: the first one identified in the Annals of Cell Biology.
- 5:46Speaker 1: What's the nitty-gritty behind how caspases orchestrate this process?
- 5:50Speaker 2: Well, Rachel, the crux of apoptosis lies in the executioner caspases,
- 5:55Speaker 2: caspase-3 and caspase-7. These enzymes are like the master keys,
- 6:01Speaker 2: slicing through DNA, nuclear, and cytoskeletal proteins, basically dismantling the
- 6:07Speaker 2: cell from within. But to raise a prelude to their activation,
- 6:10Speaker 2: with the intrinsic and extrinsic pathways setting the stage.
- 6:14Speaker 1: Exactly. And that's the crucial nuance here. So, what about
- 6:19Speaker 1: this dual pathway? How do they interact and where do
- 6:22Speaker 1: they differ?
- 6:23Speaker 2: Great question. The intrinsic pathway kicks off with mitochondrial damage
- 6:28Speaker 2: or oxidative stress, triggering the release of cytochrome C. This
- 6:32Speaker 2: sets off a chain reaction, activating caspase-9, which in turn
- 6:38Speaker 2: slices through caspase-3 and negative 7. On the other side,
- 6:42Speaker 2: the extrinsic pathway triggers when a death receptor on the
- 6:46Speaker 2: cell surface binds to an initiator ligand. This also sets
- 6:49Speaker 2: off a cascade, but it's more like a direct hit
- 6:52Speaker 2: to caspase-8.
- 6:54Speaker 1: Right. And that's the interesting contrast between the two. But
- 6:59Speaker 1: we have another player on the scene, necrosis. How does
- 7:03Speaker 1: it differ from apoptosis, and what's the role of the
- 7:06Speaker 1: membrane integrity here?
- 7:08Speaker 2: Absolutely. Necrosis is much more straightforward and less regulated, often
- 7:13Speaker 2: resulting from acute injuries. The cell swells up, the plasma
- 7:18Speaker 2: membrane breaks down, and the contents spill out. This triggers
- 7:22Speaker 2: inflammation as the leaky cell prompts the release of pro-inflammatory
- 7:26Speaker 2: molecules like cytokines and damps. It's more like the cell
- 7:30Speaker 2: goes out with a bang, leaving a mess behind.
- 7:33Speaker 1: And then we have pyroptosis, which is particularly fascinating because
- 7:37Speaker 1: of its inflammatory aspect. Can you break down the role
- 7:41Speaker 1: of gastrumin proteins here?
- 7:43Speaker 2: Certainly. Pyroptosis is driven by gastrumin proteins forming pores in
- 7:47Speaker 2: the cell membrane, essentially popping the cell open and releasing
- 7:51Speaker 2: inflammatory cytokines. This process is rapid, happening within 30 minutes,
- 7:57Speaker 2: and it's a critical component of the immune response, especially
- 8:00Speaker 2: in fighting off infections. It's like the cell decides to
- 8:04Speaker 2: break out and alert the immune system, even if it
- 8:07Speaker 2: means its own demise.
- 8:08Speaker 1: And necroptosis? The programmed version of necrosis is triggered by
- 8:12Speaker 1: RIP1 and RIP3. The debate around these pathways is thick.
- 8:18Speaker 1: Do you see overlap in how these proteins interact with
- 8:21Speaker 1: different pathways?
- 8:22Speaker 2: Absolutely. It's a big question mark. The roles of caspases
- 8:26Speaker 2: in necroptosis, for instance, throw a wrench into the dichotomy
- 8:29Speaker 2: between programmed and uncontrolled cell death. And even in pyroptosis,
- 8:34Speaker 2: Gasterman is a key player. but how it integrates with
- 8:38Speaker 2: other pathways remains a subject of intense research.
- 8:41Speaker 1: Right, and all of this complexity leads to some fascinating
- 8:44Speaker 1: therapeutic opportunities. How do researchers think we can precisely manipulate
- 8:50Speaker 1: these pathways to improve outcomes?
- 8:52Speaker 2: The goal is to develop drugs that specifically target caspases,
- 8:56Speaker 2: necrototic proteins, or gastrumin pores. By understanding these mechanisms, we
- 9:01Speaker 2: might be able to turn programmed cell death on and
- 9:04Speaker 2: off with precision. offering new avenues for treating inflammatory diseases
- 9:09Speaker 2: in cancer. The future of cell death research is not
- 9:12Speaker 2: just about understanding, but also about application.
- 9:15Speaker 1: So, let's talk about the fine lines between apoptosis and
- 9:18Speaker 1: other forms of cell death. It's really fascinating how closely
- 9:22Speaker 1: intertwined these mechanisms can be, especially in the context of
- 9:26Speaker 1: chronic illnesses.
- 9:27Speaker 2: Absolutely. Take, for instance, the overlap in signaling pathways. Caspases,
- 9:33Speaker 2: those key players in apoptosis, can also trigger necroptosis. In
- 9:38Speaker 2: some cases, the same proteins might be involved in both processes,
- 9:42Speaker 2: making it hard to distinguish between them.
- 9:44Speaker 1: Right, and that's the crucial nuance here. For example, in inflammation,
- 9:49Speaker 1: we see this interesting contradiction. Caspase-8, typically a player in apoptosis,
- 9:56Speaker 1: can also form pores in the cell membrane, leading to
- 9:59Speaker 1: what we call pyroptosis. It's almost like one protein can
- 10:04Speaker 1: play a role in multiple cell death pathways.
- 10:06Speaker 2: Exactly which brings up an interesting contradiction. Consider the case
- 10:10Speaker 2: of chronic autoimmune disorders. These conditions often exhibit signs of
- 10:15Speaker 2: both inflammation and programmed cell death. The challenge is to
- 10:19Speaker 2: understand whether the inflammation is driving apoptosis or necroptosis, or
- 10:24Speaker 2: if it's a result of one.
- 10:26Speaker 1: Wait, but how does that actually play out in practice?
- 10:29Speaker 1: For instance, in autoimmunity, you could have an immune cell
- 10:33Speaker 1: that's triggered to die through apoptosis, but then a factor
- 10:37Speaker 1: comes in and converts it into a necroptotic cell, amplifying
- 10:41Speaker 1: the inflammatory response. This interplay can make treatment tricky.
- 10:45Speaker 2: That's wild when you look at the raw numbers. Studies
- 10:49Speaker 2: show that in autoimmune conditions, a significant portion of cell
- 10:53Speaker 2: death appears to be programmed, but the exact mechanisms can
- 10:57Speaker 2: be hard to pin down. This gray area is where
- 11:00Speaker 2: the real science gets exciting.
- 11:02Speaker 1: Exactly. And let's not forget about the regulatory control. There
- 11:07Speaker 1: are proteins like RIP1 and RIP3 that can switch a
- 11:11Speaker 1: cell from apoptosis to necroptosis. Understanding their precise role could
- 11:16Speaker 1: offer new therapeutic avenues.
- 11:18Speaker 2: True. And think of the potential here. If we can
- 11:22Speaker 2: identify the exact conditions that trigger one pathway over the other,
- 11:26Speaker 2: we could design drugs that manipulate cell death for therapeutic gain.
- 11:31Speaker 2: Imagine being able to turn off harmful inflammation in autoimmune
- 11:35Speaker 2: disorders precisely by targeting these pathways.
- 11:38Speaker 1: Right. And it's not just about the treatment of diseases.
- 11:41Speaker 1: It's about refining our fundamental understanding of how cells die.
- 11:45Speaker 1: That's the real push in this research. It's not just
- 11:48Speaker 1: about what we know, but how we can use that
- 11:51Speaker 1: knowledge to improve human health.
- 11:52Speaker 2: Yes, and as we progress, we are likely to uncover
- 11:56Speaker 2: even more nuanced interactions. The complexity of cell death is
- 12:00Speaker 2: just starting to unravel, and it's a thrilling field to
- 12:04Speaker 2: be in.
- 12:04Speaker 1: The therapeutic potential of targeting cell death pathways sounds promising,
- 12:09Speaker 1: but there is still a lot to figure out. For example,
- 12:13Speaker 1: how do we ensure that the drugs we design are
- 12:16Speaker 1: both specific and safe.
- 12:18Speaker 2: Exactly right now, the challenge is balancing specificity with efficacy. Take,
- 12:23Speaker 2: for instance, the case of feroptosis. It's emerged as a
- 12:27Speaker 2: crucial mechanism in chronic inflammation, but developing drugs that target
- 12:31Speaker 2: this pathway without causing unwanted cell damage is still tricky.
- 12:35Speaker 1: Absolutely. And how do we navigate the overlap between different
- 12:39Speaker 1: cell death pathways? For example, the intrinsic and extrinsic pathways
- 12:43Speaker 1: of apoptosis can be triggered by similar stimuli, making it
- 12:47Speaker 1: hard to design a drug that only targets the pathway
- 12:50Speaker 1: without affecting others.
- 12:52Speaker 2: That's a great point. The interactions between these pathways are complex.
- 12:57Speaker 2: Take the role of ROAS reactive oxygen species, for instance.
- 13:01Speaker 2: High levels of ROAS can trigger both apoptosis and necroptosis,
- 13:06Speaker 2: and it's not always clear which pathway will dominate.
- 13:09Speaker 1: Right. Speaking of which, let's zoom in on chronic inflammation.
- 13:13Speaker 1: Targeting inflammation with drugs that modulate cell death might be
- 13:17Speaker 1: the key. What are some of the latest findings that
- 13:19Speaker 1: could help us design such drugs?
- 13:21Speaker 2: Well, one promising area is the role of specific inhibitors
- 13:25Speaker 2: of protein kinases. For instance, Rhode Island PK-1 inhibitors have
- 13:30Speaker 2: been shown to block necroptosis, potentially alleviating inflammation. But the
- 13:35Speaker 2: challenge is ensuring these inhibitors don't also affect other kinases
- 13:40Speaker 2: involved in different pathways.
- 13:41Speaker 1: And this isn't just hypothetical. There are already clinical trials
- 13:45Speaker 1: underway testing these inhibitors for conditions like Crohn's disease and psoriasis.
- 13:52Speaker 1: But the long-term effects need to be carefully monitored.
- 13:55Speaker 2: Absolutely. Another angle is the potential of therapeutic antibodies targeting
- 14:00Speaker 2: caspases or other key executioners in apoptosis. These could be
- 14:04Speaker 2: highly specific, but again, ensuring they only target the intended
- 14:08Speaker 2: cell populations is crucial.
- 14:10Speaker 1: Indeed. And what about the future outlook? Are we on
- 14:14Speaker 1: the cusp of significant breakthroughs in this field?
- 14:17Speaker 2: The field is certainly dynamic. Advances like CRISPR and gene
- 14:21Speaker 2: editing could help us better understand these pathways at a
- 14:24Speaker 2: molecular level. This could lead to more precise drug design,
- 14:28Speaker 2: targeting the exact proteins and pathways involved.
- 14:31Speaker 1: And with that, I believe the key is not just
- 14:33Speaker 1: targeting cell death pathways, but understanding the complex interplay between them.
- 14:39Speaker 1: It's a fascinating field. full of both challenges and opportunities.
- 14:43Speaker 2: Exactly. The potential for innovative treatments in chronic inflammation and
- 14:47Speaker 2: degenerative conditions is vast, but it will take a lot
- 14:51Speaker 2: of research, precision, and collaboration to get there.
- 14:54Speaker 1: So, as we wrap up, let's focus on the broader
- 14:57Speaker 1: implications of understanding these various cell death mechanisms. It's really
- 15:01Speaker 1: exciting to think about the potential for transformative therapeutics.
- 15:05Speaker 2: Right?
- 15:06Speaker 1: And that's the crucial nuance here. Apoptosis isn't just about
- 15:10Speaker 1: cell death. It's a key player in disease management, especially
- 15:14Speaker 1: in cancer treatment. Absolutely.
- 15:16Speaker 2: Take, for instance, the idea of selectively inducing apoptosis in
- 15:20Speaker 2: cancer cells. By understanding the exact mechanisms, we can develop
- 15:24Speaker 2: drugs that target just those cells without wreaking havoc on
- 15:27Speaker 2: the surrounding healthy ones. But it's not just about cancer.
- 15:31Speaker 2: The role of pyroptosis and necroptosis in chronic inflammation and
- 15:36Speaker 2: autoimmune disorders is equally promising.
- 15:39Speaker 1: Exactly. Which brings up an interesting contradiction. These programmed cell
- 15:44Speaker 1: death pathways can be seen as both allies and enemies
- 15:47Speaker 1: in disease management. For instance, while they help in clearing
- 15:51Speaker 1: out damaged cells in conditions like fibrosis, they can also
- 15:54Speaker 1: contribute to the damage itself. We have got to find
- 15:58Speaker 1: that balance.
- 15:59Speaker 2: That's wild when you look at the raw numbers. Think
- 16:02Speaker 2: about how CRISPR and gene editing platforms could refine this.
- 16:06Speaker 2: By understanding the molecular level mechanisms, We can design more
- 16:10Speaker 2: precise drugs. This is where the future of personalized medicine lies,
- 16:15Speaker 2: where every person's genetic makeup could dictate the exact treatment
- 16:19Speaker 2: they need.
- 16:19Speaker 1: Right. And this precision doesn't just stop at treatment. It
- 16:23Speaker 1: extends to regenerative medicine too. By understanding how these cell
- 16:27Speaker 1: death pathways interact with stem cells and tissue repair, we
- 16:30Speaker 1: could develop techniques that accelerate wound healing or even regenerate tissues.
- 16:35Speaker 1: It's like having a custom-built toolkit. for the body's natural
- 16:39Speaker 1: repair mechanisms.
- 16:41Speaker 2: That's the ultimate goal, really. Imagine being able to repair
- 16:44Speaker 2: organs damaged by diseases or injuries without invasive surgery. We
- 16:49Speaker 2: are talking about a fundamental shift in how we approach
- 16:52Speaker 2: disease management and health maintenance. It's like moving from a
- 16:56Speaker 2: one-size-fits-all approach to a tailored, targeted treatment.
- 16:59Speaker 1: Exactly. And as we mentioned earlier, these mechanisms aren't just
- 17:02Speaker 1: limited to humans. Understanding them in other organisms could lead
- 17:07Speaker 1: to breakthroughs that are applicable across species. It's an exciting
- 17:11Speaker 1: frontier in both medicine and bioengineering.
- 17:14Speaker 2: Therese, still a lot of ground to cover, of course.
- 17:17Speaker 2: We need more research to fully understand the regulatory control
- 17:21Speaker 2: over these pathways and how to exploit them without side effects.
- 17:25Speaker 2: But the potential benefits are immense. It's a thrilling time
- 17:28Speaker 2: to be a scientist working on this area.
- 17:30Speaker 1: Couldn't agree more. As we wrap up, It's clear that
- 17:34Speaker 1: the future of medicine is looking at cells in unprecedented detail.
- 17:39Speaker 1: Understanding cell death pathways is just the beginning. The real
- 17:43Speaker 1: magic happens when we can harness this knowledge for the
- 17:46Speaker 1: betterment of human health. That brings us to the end
- 17:48Speaker 1: of today's episode. Thank you so much for spending part
- 17:51Speaker 1: of your day with me. If you found this episode's
- 17:54Speaker 1: tips helpful and want to make sure you don't miss
- 17:56Speaker 1: the next conversation, please take a quick second to hit
- 18:00Speaker 1: that subscribe or follow button on whatever platform you are
- 18:03Speaker 1: listening on. It's a completely free way to support the
- 18:06Speaker 1: show and helps more people find us. This podcast is
- 18:09Speaker 1: independently produced, so if you are ever in a position
- 18:13Speaker 1: where you would like to help keep it running, we
- 18:15Speaker 1: do accept small donations. You can find a link right
- 18:18Speaker 1: in the episode description below to buy us a coffee
- 18:21Speaker 1: or contribute what you can. Every bit genuinely helps. Take
- 18:25Speaker 1: care of yourself, stay balanced, and we will talk again soon.